Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …

Background No targeted drugs are currently available against small cell lung cancer
(SCLC). BCL-2 family members are involved in apoptosis regulation and represent …

The BCL2 inhibitor venetoclax has been approved to treat different hematological
malignancies. Because there is no common genetic alteration causing resistance to …

The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …

Abstract BCL-X L and BCL-2 are key anti-apoptotic proteins and validated cancer targets.
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …

Protein biogenesis, maturation and degradation are tightly regulated processes that are
governed by a complex network of signaling pathways. The endoplasmic reticulum (ER) is …

Simple Summary Venetoclax has proven to be a promising therapy for newly diagnosed,
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …

The era of genomic medicine has allowed acute myeloid leukemia (AML) researchers to
improve disease characterization, optimize risk-stratification systems, and develop new …

Venetoclax, a B-cell lymphoma (BCL-2) inhibitor, in combination with hypomethylating
agents has become the new standard of care in elderly and unfit patients with acute myeloid …